Dotalsec

Quick links to important sections

Dotalsec

Method of action: Antidiarrheal, Obstructive

Treatment option: Irritable Bowel Syndrome

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dotalsec

What is Dotalsec?

Dotalsec is a pharmaceutical formulation containing gadoterate meglumine, which is a macrocyclic, ionic gadolinium-based contrast agent (GBCA). It is used primarily in diagnostic imaging procedures to enhance the quality of images obtained during magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA).

Mechanism of Action

As a contrast agent, Dotalsec works by altering the magnetic properties of water protons in the body's tissues. When injected into the bloodstream, the gadolinium within the molecule shortens the relaxation times of these protons. This process results in an increased signal intensity in specific areas, which improves the visualization and definition of various anatomical structures, including blood vessels and internal organs.

Clinical Application

In clinical practice, Dotalsec is utilized to help healthcare professionals identify and characterize lesions or abnormalities that may not be clearly visible on a standard MRI scan. Its macrocyclic structure is designed to hold the gadolinium ion securely within a cage-like molecular framework, allowing it to pass through the body and be excreted by the kidneys while providing the necessary contrast for the duration of the imaging session.

Dotalsec is typically administered intravenously by a healthcare professional shortly before or during the imaging procedure.

Regulatory References

  1. WHO Model List of Essential Medicines
  2. WHO Essential Medicines List - Loperamide
  3. Loperamide: MedlinePlus Drug Information

What side effects are possible with Dotalsec?

Possible Side Effects and Safety Information

The safety profile of Dotalsec (Loperamide hydrochloride) is defined by officially documented adverse reactions and regulatory constraints, categorized by frequency and the body system affected. This information is derived from government regulatory sources such as the FDA and EMA.


Frequency-Classified Adverse Reactions

The following are examples of adverse reactions reported in regulatory documentation, categorized by frequency of occurrence:

  • Common (ge 1/100): Constipation, Flatulence, Headache, Nausea, Dizziness.
  • Uncommon (ge 1/1,000): Abdominal pain, Abdominal discomfort, Dry mouth, Somnolence (drowsiness), Rash, Vomiting.
  • Rare (ge 1/10,000): Ileus (bowel obstruction), Megacolon, Hypersensitivity reactions, Loss of consciousness, Urinary retention.

Documented Serious Adverse Reactions

Regulatory agencies highlight rare but serious adverse reactions, which are often associated with high doses or misuse. These include severe Cardiac Adverse Reactions (such as Torsades de Pointes, ventricular arrhythmias) and severe Gastrointestinal Complications (Toxic Megacolon and Ileus).

Safety Considerations and Restrictions

Official labeling specifies safety considerations for certain populations and conditions:

  • Pediatric Patients: The medication is contraindicated in children less than 2 years of age due to risks of respiratory and cardiac issues.
  • Hepatic Impairment: Use requires caution in patients with reduced liver function due to the potential for increased systemic exposure and Central Nervous System (CNS) toxicity.
  • Discontinuation Criteria: The drug must be discontinued promptly if safety markers such as constipation or abdominal distension develop, due to the risk of serious complications.
  • Alertness: Caution is advised when performing tasks that require mental alertness, as effects such as dizziness or drowsiness may occur.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented manifestations and mandated emergency actions for an overdose of Dotalsec (Loperamide hydrochloride), based strictly on government regulatory documents (e.g., FDA, EMA).

Documented Overdose Manifestations

Overdose has been officially associated with severe effects, primarily on the heart and nervous system. The clinical signs documented in regulatory information include:

  • Central Nervous System (CNS) Effects: CNS depression (e.g., stupor, somnolence, loss of consciousness), miosis (pinpoint pupils), hypertonia, and respiratory depression.
  • Gastrointestinal Effects: Severe constipation, ileus, and urinary retention.
  • Serious Cardiac Events: QT interval prolongation, Torsades de Pointes, and other serious ventricular arrhythmias, which may lead to cardiac arrest and death.

When to Seek Immediate Medical Help

Regulators explicitly require seeking immediate medical attention by calling emergency services if any of the following symptoms occur after taking the medication:

  • Fainting (syncope).
  • Rapid heartbeat or irregular heart rhythm.
  • Unresponsiveness (the inability to be woken up or react normally).

Official Treatment and Monitoring

If an overdose is suspected, treatment is symptomatic and supportive. Naloxone is specified as the antidote to reverse CNS depression; however, repeated doses may be necessary. The patient must be subject to close, extended cardiac monitoring for at least 48 hours to manage the risk of serious cardiac events. Patients with hepatic dysfunction and children under 2 years of age have an increased risk of severe effects.

Therapeutic Uses of Dotalsec

What Dotalsec Treats: Main Uses and Benefits

This medication is used to help with symptoms related to inflammatory and pain-driven conditions. It is applied across domains where symptoms related to physical discomfort and inflammatory or irritative states are the primary concern. It is relevant for conditions characterized by periods of heightened symptoms, such as osteoarthritis and rheumatoid arthritis, and is generally used when short-term symptomatic assistance is needed to address acute pain.

It is relevant in contexts involving heightened systemic burden and symptoms associated with acute or episodic changes. It is applied in clinical settings that involve acute or unstable symptom patterns, providing support that helps ease the overall symptom load. By helping to address symptom clusters that may become intense or disruptive during flare-ups, it contributes to improved comfort and assists with maintaining functional comfort during symptomatic periods.


Quick Fact: Support for Symptoms of Inflammatory Joint Pain


Regulatory References

  1. National Institutes of Health (NIH) DailyMed

Eligibility and Restrictions for Use

The official regulatory documents define strict eligibility criteria for Dotalsec (Docetaxel). Use is contraindicated in several specific patient groups due to unacceptable risk, and conditional restrictions apply to others.

Populations Who Cannot Use Dotalsec

Category Regulatory Status
Hypersensitivity Contraindicated in patients with a history of severe allergic reactions to docetaxel or to drugs formulated with polysorbate 80.
Neutrophil Count Contraindicated if the absolute neutrophil count is less than 1500 cells/mm^3 prior to a treatment cycle.
Severe Liver Impairment Contraindicated/Avoided if bilirubin is above the upper normal limit (ULN) or if AST/ALT is >1.5 imes ULN concurrent with alkaline phosphatase >2.5 imes ULN.

Restricted and Special Populations

Category Regulatory Status
Pregnancy Not Recommended. The drug can cause fetal harm; women of childbearing potential and male partners must use effective contraception.
Lactation Advised Against. Women must discontinue breastfeeding due to the potential for infant risk.
Pediatric Use Safety and effectiveness are not established in the pediatric population.
Renal Impairment Undefined for dosing adjustment; use with caution.

Connection to the overall eligibility profile Regulatory documents establish the drug's eligibility profile by mandating that patients must not have specific hematologic or severe hepatic abnormalities before treatment, and they enforce strict non-eligibility for those with a history of severe hypersensitivity. Eligibility is conditional on laboratory values and is not established for children.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dotalsec has a complex interaction profile documented in official regulatory labeling, primarily defined by its susceptibility to exposure modification and potential for additive effects with co-administered substances.

Pharmacokinetic Interactions

Dotalsec is identified as a sensitive substrate of Cytochrome P450 3A4 (CYP3A4) and the efflux transporter P-glycoprotein (P-gp). Co-administration with strong CYP3A4 inhibitors (e.g., Ketoconazole, Voriconazole) significantly increases Dotalsec exposure (AUC/Cmax). Conversely, strong CYP3A4 inducers (e.g., Rifampin, St. John's Wort) lead to a critical decrease in Dotalsec concentrations, rendering these combinations contraindicated due to risk of therapeutic failure.

Contraindicated and Restricted Combinations

Interaction Type Examples of Interacting Substances/Classes
Contraindicated Combinations Strong CYP3A4 Inducers (Rifampin), Specific QTc-Prolonging Agents (Amiodarone)
Exposure-Modifying Agents Strong CYP3A4 Inhibitors (Voriconazole), P-gp Inhibitors

Drug-Food and Timing Constraints

The absorption of Dotalsec is susceptible to interference. It must be administered without food (e.g., at least one hour before or two hours after a meal) to manage exposure. A minimum two-hour separation is required between Dotalsec and the administration of antacids or other polyvalent cation-containing supplements to prevent chelation and reduced absorption.

Population-Specific Notes

The official label highlights that the exposure increase caused by CYP3A4 inhibitors is magnified in patients with mild-to-moderate hepatic impairment, necessitating a greater degree of management.

Mechanism of Action

Peripheral Modulation of the Gut's Nervous System

The mechanism of Dotalsec is initiated by its targeted binding and agonism of mu-opioid receptors located primarily in the myenteric plexus—the intrinsic nervous system of the intestinal wall. This action is peripheral, meaning it is confined to the gastrointestinal tract, and it selectively engages mechanisms that regulate overactive physiological processes in the gut.


Inhibition of Propulsive Peristalsis and Secretion

Activation of these receptors leads to the suppression of signaling sequences, specifically by inhibiting the release of excitatory neurotransmitters like acetylcholine and prostaglandins. This molecular action modifies early steps that govern gut movement, resulting in a decrease in the amplitude and frequency of propulsive peristaltic contractions of the intestinal smooth muscle. Concurrently, it contributes to a reduction in the secretion of water and electrolytes into the lumen.


Physiological Consequence: Prolonged Transit Time

The combined effects of reduced propulsive movement and decreased fluid secretion lead to a fundamental physiological adjustment: a substantial prolongation of intestinal transit time. This increase in the duration contents spend in the large intestine creates conditions for the regulation of targeted pathways, allowing for enhanced natural reabsorption of water and electrolytes, which results in the formation of a less fluid and more cohesive stool mass and reduced bowel evacuation frequency.

Dosage and Administration Information

How to Use Dotalsec

Dotalsec (Loperamide hydrochloride) is administered according to established clinical principles. The medication is used for oral administration and is available in various dosage forms, including capsules, tablets, and oral solutions.

Standard Dosing Regimens

For acute diarrhea in adults, the general principle of use involves an initial 4 mg dose, followed by 2 mg after each subsequent unformed stool. The total amount administered typically adheres to limits that restrict the dose to 8 mg to 16 mg in a 24-hour period, depending on whether use is self-medicated or under prescription supervision. In cases of chronic diarrhea, a flexible daily maintenance range of 4 mg to 8 mg is utilized, often administered as a single dose or in divided doses to control symptoms.

Administration Contexts

Frequency: For acute use, the schedule is symptom-driven, meaning doses are taken as needed following an episode, rather than at fixed time intervals. The medicine can be taken with or without food. For the acute setting, self-treatment does not exceed 48 hours without seeking clinical guidance.

Population and Procedural Rules

Use in children under two years of age is not recommended. No adjustment is required for patients who are older adults or those with renal impairment, but caution is applied when administering the medicine to patients with hepatic impairment. A procedural constraint is that the medicine is promptly discontinued if constipation or abdominal distention develops. Additionally, use of this medication is paired with appropriate fluid and electrolyte replacement therapy.

Recent Clinical Evidence

Dotalsec: Recent Clinical Evidence

Recent clinical research has investigated the use of Dotalsec (referred to as duloxetine in studies) across its approved indications, focusing on both efficacy measures and safety profiles in diverse patient populations.

Findings in Depression

A large-scale, open-label, multicenter study assessed the outcomes of Dotalsec in outpatients diagnosed with Major Depressive Disorder (MDD) in real-world clinical settings. The study reported that the treatment was associated with improvements across physician-rated scales for illness severity, as well as patient-rated measures of somatic symptoms and depressive symptomatology. These observed changes were consistent across subgroups defined by gender, age, and patient care setting. Approximately 71.4% of the participants completed the study.

Pain and Neuropathy Research

Dotalsec has been the subject of randomized, double-blind, placebo-controlled trials to evaluate its effects in the management of chronic pain conditions. Specifically, in studies of diabetic peripheral neuropathic pain (DPNP), the drug was observed to reduce pain severity compared to placebo. A pooled analysis of four randomized controlled trials in MDD also evaluated tolerability, noting that the discontinuation rate due to adverse events for Dotalsec (8.0%) was comparable to that of a common comparator drug (6.1%).

Safety and Tolerability Summary

Across multiple studies, nausea was frequently reported as a treatment-emergent adverse event associated with Dotalsec. The overall safety and tolerability profile across these clinical trials generally aligns with that of other commonly prescribed agents in its class, though specific side effects, such as a small mean increase in heart rate compared to placebo, were noted in pooled analyses. Further research continues to explore the drug's use in other pain conditions, such as acute musculoskeletal pain.

Frequently Asked Questions (FAQ)

Common questions about Dotalsec (FAQ)


Q: How long does it typically take to start feeling the effects of Dotalsec?

A: Official information indicates that the medicine can begin to slow intestinal movement within about one hour of administration. The amount of medication circulating in the bloodstream typically reaches its peak concentration within 4 to 5 hours after a dose.


Q: Can Dotalsec affect my ability to drive or operate machinery?

A: The official product information advises using caution when undertaking tasks that demand mental alertness, such as driving a car or operating machinery. This is due to the potential for known side effects, which include dizziness and drowsiness.


Q: What should I do if I experience a mild, unusual symptom after starting Dotalsec?

A: If serious symptoms like fever, bloody stools, or severe abdominal distention occur, regulatory documents mandate that the drug be discontinued immediately. If diarrhea does not improve within 48 hours, or if unusual symptoms occur, official guidance suggests communicating with a healthcare provider.


Q: Why do some people experience initial stomach upset with Dotalsec?

A: Official product documentation lists side effects such as nausea, abdominal pain, and abdominal discomfort as commonly or uncommonly reported events during clinical trials. This indicates that temporary stomach upset, such as nausea or abdominal pain, is a recognized possibility associated with the medication's use.


Q: What information is available about Dotalsec and alcohol consumption?

A: Official information suggests that avoiding or limiting alcohol use may be appropriate during treatment. This is because combining the medicine with alcohol may potentially intensify central nervous system side effects like dizziness and drowsiness.


Q: What does the patient leaflet say about discontinuing Dotalsec?

A: The medicine must be promptly discontinued if safety markers like constipation or abdominal distention develop. For use in acute diarrhea, official guidance strictly limits self-treatment to 48 hours without the involvement of a healthcare professional.


Q: Is Dotalsec the same kind of medication as other drugs for similar conditions?

A: Dotalsec is officially classified as an anti-diarrheal agent that acts as a peripheral mu-opioid receptor agonist. This classification describes its specific action primarily in the gut wall and differentiates it from other medications that work in different pharmacological ways.


Q: What are some of the most common reasons a doctor might choose Dotalsec?

A: Official documents define its main uses as the treatment of acute nonspecific diarrhea and diarrhea associated with Irritable Bowel Syndrome (IBS) (under physician diagnosis). It is also approved for the specific purpose of reducing the volume of discharge from an ileostomy.


Q: What happens if I miss a dose of Dotalsec?

A: Since the medicine is typically taken as needed for symptoms, official patient guidance for acute use advises that a patient should take the usual dose after the next unformed stool. The patient guidance emphasizes that an extra amount should not be taken to try and compensate for a missed dose.


Q: Is it okay to take over-the-counter pain relievers while using Dotalsec?

A: Official labeling requires caution regarding potential drug interactions, particularly those that affect the metabolism of Dotalsec. Due to the potential for complex interactions, official sources advise that all concurrent medications, including over-the-counter products, be reviewed by a healthcare provider.


Q: How is Dotalsec different from [Specific Comparator Drug]? (Informational only)

A: Dotalsec (Loperamide) is widely available over-the-counter and is not classified as a controlled substance by regulatory agencies. Certain other medications in the same pharmacological class used to treat diarrhea are only available by prescription and are classified as controlled substances.


Q: Do studies suggest Dotalsec is safe for use during pregnancy?

A: Official documentation states that the drug is not recommended during pregnancy due to the potential for fetal harm. Women of childbearing potential, along with their male partners, are officially advised to use effective contraception during the course of treatment.


Q: Is Dotalsec available as a generic medicine?

A: Yes, the active ingredient in Dotalsec, which is Loperamide hydrochloride, is widely available in lower-cost generic formulations in addition to the brand-name products.


Q: Are there any specific lifestyle changes recommended alongside taking Dotalsec?

A: Regulatory documents emphasize that the use of this medication should be accompanied by appropriate fluid and electrolyte replacement therapy. This is considered an essential part of managing diarrhea to prevent or correct dehydration.


Q: Is it true that Dotalsec can interact with blood pressure medications?

A: Official warnings advise caution or avoidance when combining this medication with certain drugs known to prolong the QT interval (a measure of heart rhythm). It is generally advised that all concurrent medications, including those for blood pressure, be reviewed by a healthcare provider.


Q: Does the body build up a tolerance to Dotalsec over time?

A: Official regulatory documents explicitly state that tolerance to the antidiarrheal effect of Dotalsec has not been observed with its proper use at the recommended dosages.


Q: Are there any specific genetic factors that affect how Dotalsec works?

A: The drug's processing in the body involves specific enzymes like CYP3A4 and a transporter protein called P-glycoprotein. The activity of these pathways can be affected by natural biological variability, which may influence how the medicine is processed in different individuals.


Q: What is the typical duration of treatment with Dotalsec?

A: For acute diarrhea, most people take the medicine for only 1 to 2 days. If using the over-the-counter version, official guidance strictly advises not taking it for more than 48 hours without consulting a healthcare provider.


Q: Are there any specific laboratory tests required before starting Dotalsec?

A: Specific blood test results, such as certain liver function or white blood cell counts, are referenced in official labeling as criteria for when the drug cannot be used. This indicates that these laboratory values are relevant to patient eligibility and must be managed.


Q: Is it normal to feel tired when first starting Dotalsec?

A: Official documentation lists side effects like somnolence (drowsiness) and dizziness as 'uncommon' occurrences in clinical trials. While it is a known possibility, it is not a universally expected experience when starting the medication.


Q: Why is Dotalsec sometimes prescribed for a seemingly unrelated condition?

A: In addition to general diarrhea, the official labeling approves the medication for a specialized use: reducing the volume of discharge from an ileostomy. This is a specific approved indication related to the digestive system.


Q: Can I take other prescription medications with Dotalsec?

A: The official labeling documents a complex interaction profile with other medicines, particularly those affecting the CYP3A4 enzyme or the P-glycoprotein transporter. Official guidance emphasizes that patients should provide a complete list of all medications to their healthcare provider.


Q: Are there any known interactions between Dotalsec and herbal supplements?

A: Official warnings specifically mention that certain herbal supplements, such as St. John's Wort, can significantly interfere with the body's processing of the drug. The general advice is to consult a healthcare provider regarding all herbal and natural supplements.


Q: How quickly does Dotalsec leave the system after the last dose?

A: The time it takes for half of the dose to be eliminated from the bloodstream is reported to be between 9.1 to 14.4 hours, with an average of about 11 hours. Elimination of the medication primarily occurs through the feces.


Q: What distinguishes Dotalsec from older treatments for the same disease?

A: Dotalsec is often highlighted for acting primarily peripherally, meaning its main effects are confined to the gut wall. This mechanism means it does not possess the same risk profile for central nervous system effects or abuse potential as some older, centrally-acting antidiarrheal treatments.


Q: Can men and women take Dotalsec for the same condition?

A: Clinical trials and efficacy studies of the medicine are conducted across various patient subgroups, including gender. These studies report consistent outcomes, which indicates the drug is considered appropriate for use in both male and female adults for approved indications.


Q: What does the official evidence say about Dotalsec's success rates?

A: Reports from official clinical trials indicate that the medicine is associated with significant reductions in diarrhea symptoms. Its consistent clinical effectiveness is recognized globally by organizations like the World Health Organization.


Q: Is Dotalsec an immunosuppressant?

A: No, official classifications define Dotalsec as an antidiarrheal agent and a peripheral mu-opioid receptor agonist. It is not classified as an immunosuppressant.


Q: How is the long-term safety of Dotalsec monitored by health authorities?

A: Health authorities, such as the FDA, conduct post-market surveillance to monitor for new or serious risks that emerge after a drug is widely available. Safety warnings, especially those concerning misuse leading to serious events like cardiac adverse reactions, are issued based on this ongoing monitoring.

How should Dotalsec be stored and disposed of?

How to Store and Dispose of Dotalsec

Dotalsec (Loperamide HCl) must be stored according to specific regulatory requirements to maintain its stability and effectiveness.


Storage Conditions

Requirement Regulatory Statement
Temperature Store at controlled room temperature between 20 C and 25 C (68 F and 77 F).
Protection Keep the container tightly closed to protect the product. Do not freeze.
Child Safety Keep out of the sight and reach of children at all times.

Disposal Instructions

Unused or expired Dotalsec must be disposed of responsibly. The medication must not be flushed down the toilet or sink, as it is not listed on the FDA's flush list. Disposal should be completed through an authorized drug take-back program. If a take-back option is unavailable, the medication may be mixed with an unappealing substance, sealed in a container, and discarded in the household trash, following local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dotalsec found in:

A-Z Index: